Click on a filter below to refine your search. Remove a filter to broaden your search.
Excellent tolerability was seen, with no changes in blood pressure, minimal reports of sedation and minimal dissociation.
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
Polypharmacy increased, peaking at 43.0% in 2017 to March 2020; hyperpolypharmacy increased during 1999-2000 to 2007-2008.